Payment overview · 2025
General Payments
$271.49
3 reported records · 3 companies
Healthcare provider profile · identity verified
Hudson H Daneshvar, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · LIVONIA, MI · NPI 1770548232
Verified facts
What the public records show
CMS Open Payments records show Hudson H Daneshvar, M.D received $271.49 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 46.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.80 | 44.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.70 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.49 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 65 |
| Eliquis | Apixaban | 379 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 43 |
| Losartan Potassium | Losartan Potassium | 309 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 44 |
| Lisinopril | Lisinopril | 270 | 43 |
| Donepezil Hcl | Donepezil Hcl | 235 | 30 |
| Furosemide | Furosemide | 223 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 32 |
| Carvedilol | Carvedilol | 189 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 32 |
| Omeprazole | Omeprazole | 158 | 31 |
| Gabapentin | Gabapentin | 152 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 21 |
| Simvastatin | Simvastatin | 150 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 38 |
| Potassium Chloride | Potassium Chloride | 141 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 21 |
| Myrbetriq | Mirabegron | 128 | 12 |
| Metformin Hcl | Metformin Hcl | 114 | 26 |
| Mirtazapine | Mirtazapine | 104 | 20 |
| Allopurinol | Allopurinol | 100 | 14 |
| Sertraline Hcl | Sertraline Hcl | 96 | 20 |
| Bumetanide | Bumetanide | 88 | 20 |
| Clonidine Hcl | Clonidine Hcl | 86 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 79 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 14 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 18 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 69 | suppressed |
| Famotidine | Famotidine | 62 | 14 |
| Finasteride | Finasteride | 61 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | 15 |
| Alprazolam | Alprazolam | 55 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 24 |
| Atenolol | Atenolol | 49 | suppressed |
| Spironolactone | Spironolactone | 47 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Latanoprost | Latanoprost | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 22 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Letrozole | Letrozole | 40 | suppressed |
| Nystatin | Nystatin | 37 | 23 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Nystop | Nystatin | 34 | 18 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 16 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Prednisone | Prednisone | 33 | 24 |
| Azithromycin | Azithromycin | 32 | 27 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 13 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Digoxin | Digoxin | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.49 · 3 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, BREZTRI, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error